Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects*
• Benzenesulfonates / administration & dosage
• Benzenesulfonates / adverse effects*
• Carcinoma, Squamous Cell / chemically induced*
• Carcinoma, Squamous Cell / pathology
• Carcinoma, Squamous Cell / surgery
• Cell Transformation, Neoplastic / pathology
• Female
• Follow-Up Studies
• Humans
• Keratinocytes / pathology*
• Keratoacanthoma / chemically induced*
• Keratoacanthoma / pathology
• Keratoacanthoma / surgery
• Male
• Middle Aged
• Niacinamide / analogs & derivatives
• Phenylurea Compounds
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects*
• Pyridines / administration & dosage
• Pyridines / adverse effects*
• Skin / drug effects*
• Skin / pathology
• Skin Neoplasms / chemically induced*
• Skin Neoplasms / pathology
• Skin Neoplasms / surgery
• Sorafenib
• Time Factors